City Therapeutics, a clinical-stage biotechnology firm specializing in the development of small interfering RNA (siRNA) therapies, successfully priced its upsized initial public offering (IPO) late Thursday, raising $200 million to accelerate its efforts in expanding the reach of RNA interference (RNAi) medicines. The Cambridge, Massachusetts-based company offered 11.1 million shares of common stock at $18.00 per share, the midpoint of its previously announced price range of $17.00 to $19.00. The final deal size represented a significant increase from the 9.7 million shares originally planned, reflecting robust investor appetite for the company’s platform technology. Trading of the shares commenced Friday on the Nasdaq Global Select Market under the ticker symbol “CTY.”
This financial milestone marks a pivotal moment for City Therapeutics as it seeks to transcend the historical limitations of RNAi technology. While RNAi has proven highly effective at silencing disease-causing genes in the liver, the company is part of a new vanguard of biotechs engineering delivery systems capable of reaching diverse tissues across the human body, including the cardiovascular system, the eyes, and the central nervous system. With its lead candidate already in human trials for cardiovascular indications, City Therapeutics is positioning itself to lead a secondary wave of innovation in a field that many analysts believe is on the cusp of an era of exponential growth.
The Evolution of RNA Interference and the City Therapeutics Mission
RNA interference is a biological process in which RNA molecules inhibit gene expression or translation by neutralizing targeted mRNA molecules. Since the discovery of the mechanism earned Andrew Fire and Craig Mello the Nobel Prize in 2006, the pharmaceutical industry has worked to harness this "gene silencing" capability to treat intractable diseases. The field was largely pioneered by Alnylam Pharmaceuticals, which successfully brought four RNAi drugs to market. However, these therapies primarily utilize the GalNAc delivery platform, which is highly optimized for the liver but less effective for other organs.
City Therapeutics was founded in 2023 with the specific goal of solving the "delivery problem." By developing proprietary "triggers"—the actual RNA sequences that silence mRNA—and novel tissue-targeting ligands, the company aims to broaden the therapeutic window of RNAi. This mission is bolstered by the presence of John Maraganore, Ph.D., as co-founder and executive chair. As the founding CEO of Alnylam, Maraganore is widely credited with navigating the first generation of RNAi drugs through the complex regulatory and technical hurdles of the last two decades. His involvement with City Therapeutics signals a strategic attempt to replicate Alnylam’s success while applying the technology to more prevalent, non-liver-based diseases.
In its IPO filing with the Securities and Exchange Commission (SEC), City Therapeutics drew a historical parallel between the current state of RNAi and the early days of monoclonal antibodies. In the mid-1990s, monoclonal antibodies were a niche modality; today, they represent a massive segment of the global drug market with over 150 approved products. City argues that with approximately 100 RNAi programs currently in clinical development across the industry, the modality is poised for a similar trajectory of diversification and commercial dominance.
Clinical Pipeline and Lead Candidate CITY-FXI
The cornerstone of City’s current clinical efforts is CITY-FXI, an siRNA therapy designed to suppress the production of Factor XI (FXI). Factor XI is a protein in the coagulation cascade that contributes to the formation of harmful blood clots (thrombosis) but plays a relatively minor role in normal wound healing (hemostasis). By silencing the gene responsible for FXI, City aims to create a "safer" anticoagulant that prevents strokes and clots without the high risk of life-threatening bleeding associated with traditional blood thinners like warfarin or direct oral anticoagulants (DOACs).
CITY-FXI utilizes a ligand that targets the low-density lipoprotein receptor-related protein 1 (LRP1), a delivery mechanism designed to extend the drug’s reach. The company is currently conducting a Phase 1 study in healthy volunteers. Preliminary data released by the company indicates that a single injection of CITY-FXI resulted in a dose-dependent knockdown of FXI levels, ranging from 60% at the lowest dose to 85% at the highest dose. Crucially, the drug was reported to be generally well-tolerated, with no significant safety concerns identified in the early cohorts.
The commercial potential for CITY-FXI is vast, with applications including secondary stroke prevention, atrial fibrillation in patients who cannot tolerate standard blood thinners, and the prevention of venous thromboembolism (VTE) following major surgeries. City plans to initiate a Phase 2 trial in mid-2027 focusing on patients undergoing total knee arthroplasty—a population at high risk for post-surgical clots.
However, the path to market is not without competition. ADARx Pharmaceuticals, another major player in the siRNA space, recently raised $535 million to advance its own FXI-targeting program. The race between City and ADARx highlights the industry’s intense interest in FXI as a target, as well as the broader shift toward using RNAi for large-market cardiovascular indications rather than just rare genetic disorders.
Diversifying into Ophthalmology and Hematology
Beyond cardiovascular health, City Therapeutics is advancing two preclinical programs toward the clinic, targeting eye diseases and blood disorders.
CITY-RBP4 is an siRNA designed to target the mRNA for Retinol Binding Protein 4 (RBP4). The primary indication is Stargardt disease, a rare inherited form of macular degeneration that leads to progressive vision loss. By reducing RBP4 levels, the therapy aims to slow the accumulation of toxic vitamin A byproducts in the retina. City expects to begin a Phase 1 trial for Stargardt disease later this year, with data anticipated in early 2028. Furthermore, the company sees potential for CITY-RBP4 in geographic atrophy, a more common form of advanced age-related macular degeneration. A Phase 2 trial for geographic atrophy is slated to begin in late 2025.
The third major pillar of the pipeline is CITY-TFR2, targeting Transferrin Receptor 2 to treat anemia associated with myelofibrosis. Myelofibrosis is a rare bone marrow cancer that disrupts the body’s normal production of blood cells. By reducing TFR2 levels, the siRNA therapy is designed to lower hepcidin levels, thereby making more iron available for the production of red blood cells. City is also exploring the use of this candidate for anemia related to chronic kidney disease and inflammatory bowel disease. Clinical testing for CITY-TFR2 will include an investigator-initiated study in China and a Phase 1/2 study, with approximately $40 million of the IPO proceeds earmarked for these efforts.
Strategic Alliances and Financial Foundation
City Therapeutics’ technological platform has already garnered significant interest from established pharmaceutical giants. The company has secured strategic research collaborations with Bausch + Lomb and Biogen, focusing on ophthalmology and central nervous system (CNS) disorders, respectively. These alliances not only provide City with specialized expertise in complex therapeutic areas but also provide a steady stream of collaboration revenue, which totaled $6.3 million in the first half of 2024.
Financially, City entered the public markets from a position of strength. As a private entity, the company raised nearly $239 million, including a $99.5 million Series B round in July 2024. Arch Venture Partners remains the company’s largest shareholder, maintaining a 26.7% stake following the IPO.
As of September 30, 2024, the company reported an unaudited cash position of $141.9 million. When combined with the $200 million in gross proceeds from the IPO, City Therapeutics estimates it has a cash runway that will fund operations into late 2028. The company has outlined a detailed spending plan for these funds:
- $30 million for the continued clinical development of CITY-FXI.
- $20 million for CITY-RBP4’s Phase 1 and preparation for later-stage trials.
- $40 million for the CITY-TFR2 clinical programs in China and the U.S.
- $70 million for the advancement of the core platform technology and the development of new preclinical candidates.
Broader Implications for the Biotech Sector
The successful IPO of City Therapeutics serves as a barometer for the "RNAi 2.0" movement. For years, the biotech sector has grappled with the "delivery bottleneck," where promising genetic therapies were confined to the liver because that is where the body naturally clears nanoparticles and conjugates. City’s ability to raise $200 million in a volatile market environment suggests that investors are increasingly confident in the industry’s ability to engineer its way into other tissues.
The move toward common diseases like stroke and anemia also represents a shift in the business model for RNAi. While the first generation of these drugs focused on "orphan" diseases with high price tags and small patient populations, City is targeting indications that affect millions. This shift requires larger clinical trials and more robust manufacturing capabilities, but it also offers the potential for blockbusters that could redefine standard-of-care treatments across multiple medical disciplines.
As City Therapeutics transitions to a public company, the focus will shift to its clinical data readouts. The biotechnology industry will be watching closely to see if the high levels of gene knockdown observed in the early CITY-FXI data translate into meaningful clinical outcomes without the safety pitfalls that have derailed previous generations of genomic medicines. If City can deliver on its promise to silence disease-driving proteins throughout the body, it may well fulfill its own prediction of becoming a cornerstone of modern medicine, much like the monoclonal antibody revolution before it.
